Search results
Showing 2191 to 2205 of 9087 results
CM-AT for behaviours associated with autism in children and young people [ID6731]
Awaiting development Reference number: GID-TA11955 Expected publication date: TBC
Obinutuzumab for treating primary membranous nephropathy [ID6751]
Awaiting development Reference number: GID-TA11983 Expected publication date: TBC
School-based interventions: physical and mental health and wellbeing promotion
In development Reference number: GID-QS10070 Expected publication date: TBC
Infant, children and young people's experience of health care
Awaiting development Reference number: GID-QS10102 Expected publication date: TBC
Awaiting development Reference number: GID-QS10103 Expected publication date: TBC
Awaiting development Reference number: GID-QS10105 Expected publication date: TBC
Awaiting development Reference number: GID-QS10106 Expected publication date: TBC
Awaiting development Reference number: GID-TA11876 Expected publication date: TBC
Bipolar disorder: assessment and management (extraordinary review)
In development Reference number: GID-NG10380 Expected publication date: TBC
Tideglusib for treating congenital or childhood onset myotonic dystrophy [ID3915]
Awaiting development Reference number: GID-TA10791 Expected publication date: TBC
Maralixibat for treating cholestatic pruritus in Alagille syndrome [ID3941]
In development Reference number: GID-TA10832 Expected publication date: TBC
Itopride hydrochloride for treating gastrointestinal symptoms of functional dyspepsia [ID6745]
Awaiting development Reference number: GID-TA11979 Expected publication date: TBC
Awaiting development Reference number: GID-TA10833 Expected publication date: TBC
Nipocalimab for treating generalised myasthenia gravis [ID6562]
Awaiting development Reference number: GID-TA11492 Expected publication date: TBC
Inebilizumab for treating generalised myasthenia gravis [ID6587] [TSID12110]
Awaiting development Reference number: GID-TA11667 Expected publication date: TBC